Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Recurso digital |
| Lenguaje: | |
| Publicado: |
Zenodo
2025
|
| Materias: | |
| Acceso en línea: | https://doi.org/10.5281/zenodo.15185106 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Tabla de Contenidos:
- <p><span>The mechanism of action (MOA) and effectiveness of vonoprazan, a potassium-competitive acid blocker (P-CAB), are very different from those of conventional proton pump inhibitors (PPIs) such as omeprazole and esomeprazole.Unlike PPIs, which require activation in an acidic environment and irreversibly inhibit the H⁺/K⁺-ATPase enzyme, Vonoprazan directly and reversibly blocks this enzyme without requiring prior activation. As<span> </span>a<span> </span>result,<span> </span>gastric<span> </span>acid<span> </span>secretion can be suppressed<span> </span>more<span> </span>rapidly ,<span> </span>potently , and<span> </span>sustainably . Studies have shown that Vonoprazan achieves higher gastric pH levels more quickly & maintains them for a longer duration compared to PPIs, making it particularly effective for patients with severe acid-related disorders. Additionally, it is more stable in acidic conditions, providing consistent efficacy even in cases where PPIs may be less effective, such as Helicobacter pylori eradication or refractory gastro-esophageal reflux disease (GERD)</span><span lang="EN-US">. </span></p>